更新于：2024-11-01

Kanazawa University Hospital

Japan

更新于：2024-11-01

概览

概览

关联

项与 Kanazawa University Hospital 相关的临床试验

JPRN-UMIN000048411 / CompletedIIT

An observational study of the association between sleep disturbances and salivary biomarkers - An observational study of the association between sleep disturbances and salivary biomarkers

开始日期2022-07-20

申办/合作机构

Kanazawa University Hospital

JPRN-UMIN000048039 / SuspendedIIT

Observational study of communication using artificial larynx for ventilator patients - Observational study of communication using artificial larynx for ventilator patients

开始日期2022-06-13

申办/合作机构

Kanazawa University Hospital

JPRN-UMIN000045590 / SuspendedIIT

Effect of COmmunicating health guidance and renal cardiovascular event risk-related items on health-related qOL and renal protection for diabetic patients with CKD - Effect of COmmunicating health guidance and renal cardiovascular event risk-related items on health-related qOL and renal protection for diabetic patients with CKD

开始日期2021-11-01

申办/合作机构

Kanazawa University Hospital

100 项与 Kanazawa University Hospital 相关的临床结果

登录后查看更多信息

0 项与 Kanazawa University Hospital 相关的专利（医药）

登录后查看更多信息

2,000

项与 Kanazawa University Hospital 相关的文献（医药）

2024-11-01·Annals of Nuclear Medicine

Recent advancements in new tracers from first-in-human studies

Review

作者: Wakabayashi, Hiroshi ; Inui, Yoshitaka ; Nakamoto, Yuji ; Hanaoka, Hirofumi ; Hotta, Masatoshi

AbstractRecent advancements in the development of positron emission tomography (PET) tracers have significantly enhanced our ability to image neuroinflammatory processes and neurotransmitter systems, which are vital for understanding and treating neurodegenerative and psychiatric disorders. Similarly, innovative tracers in oncology provide detailed images of the metabolic and molecular characteristics of tumors, which are crucial for tailoring targeted therapies and monitoring responses, including radiotherapy. Notable advancements include programmed death ligand 1 (PD-L1)-targeting agents for lung cancer, prostate-specific membrane antigen-based tracers for prostate cancer, chemokine receptor-targeting agents for hematological malignancies, human epidermal growth factor receptor 2 (HER2)-targeting tracers for various cancers, Claudin 18 based tracers for epithelial tumors, glutamine tracers for colorectal cancer, and ascorbic acid analogs for assessing cancer metabolism and therapy efficacy. Additionally, novel tracers have been developed for non-neurological and non-oncological applications, including adrenal imaging, amyloidosis, and human immunodeficiency virus (HIV) infection. This overview focuses on the newly developed tracers, particularly those used in neurology and oncology.

2024-09-25·Circulation Journal

Validation of the Diagnostic Criteria for IgG4-Related Periaortitis/Periarteritis and Retroperitoneal Fibrosis (IgG4PA/RPF) 2018, and Proposal of a Revised 2023 Version for IgG4-Related Cardiovascular/Retroperitoneal Disease

Article

作者: Mizushima, Ichiro ; Obitsu, Yukio ; Kasashima, Fuminori ; Matsumoto, Yasushi ; Amiya, Eisuke ; Shintani-Domoto, Yukako ; Fujinaga, Yasunari ; Izawa, Atsushi ; Takayama, Toshio ; Takahashi, Masaaki ; Nagasawa, Tasuku ; Kasashima, Satomi ; Saeki, Takako ; Yoshifuji, Hajime ; Ozawa, Makiko ; Takahashi, Hiroki ; Ito, Eisaku ; Sawa, Naoki ; Shimada, Shogo ; Kanno, Hiroyuki ; Katsumata, Takahiro ; Ishizaka, Nobukazu ; Kawano, Mitsuhiro ; Ohki, Takao ; Morikage, Noriyasu ; Oyama-Manabe, Noriko

BACKGROUNDIn 2018, diagnostic criteria were introduced for IgG4-related periaortitis/periarteritis and retroperitoneal fibrosis (PA/RPF). This study assessed the existing criteria and formulated an improved version.METHODS AND RESULTSBetween August 2022 and January 2023, we retrospectively analyzed 110 Japanese patients diagnosed with IgG4-related disease (IgG4-RD) involving cardiovascular and/or retroperitoneal manifestations, along with 73 non-IgG4-RD patients ("mimickers") identified by experts. Patients were stratified into derivation (n=88) and validation (n=95) groups. Classification as IgG4-RD or non-IgG4-RD was based on the 2018 diagnostic criteria and various revised versions. Sensitivity and specificity were calculated using experts' diagnosis as the gold standard for the diagnosis of true IgG4-RD and mimickers. In the derivation group, the 2018 criteria showed 58.5% sensitivity and 100% specificity. The revised version, incorporating "radiologic findings of pericarditis", "eosinophilic infiltration or lymphoid follicles", and "probable diagnosis of extra-PA/-RPF lesions", improved sensitivity to 69.8% while maintaining 100% specificity. In the validation group, the original and revised criteria had sensitivities of 68.4% and 77.2%, respectively, and specificities of 97.4% and 94.7%, respectively.CONCLUSIONSProposed 2023 revised IgG4-related cardiovascular/retroperitoneal disease criteria show significantly enhanced sensitivity while preserving high specificity, achieved through the inclusion of new items in radiologic, pathological, and extra-cardiovascular/retroperitoneal organ categories.

2024-09-01·Cardiovascular Pathology

Clinicopathological features of immunoglobulin G4-related constrictive pericarditis

Article

作者: Ikeda, Hiroko ; Yamamoto, Hinako ; Kawashima, Atsuhiro ; Kasashima, Fuminori ; Takemura, Hirofumi ; Matsumoto, Yasushi ; Kasashima, Satomi ; Ozaki, Satoru ; Kurose, Nozomu

AIMConstrictive pericarditis (CP) is characterised by scarring fibrosis and a loss of pericardial elasticity, which causes heart failure. IgG4 (immunoglobulin G4)-related disease (IgG4-RD) is a systemic fibro-inflammatory disease characterised by the infiltration of IgG4-immunopositive plasmacytes and high serum IgG4 levels that frequently shape tumorous lesions. Although pericardial involvement of IgG4-RD is rare, with indications of CP, pericardial effusion and irregular masses, the clinical and pathological features remain unclear. In this study, we examined the relationship between CP and IgG4-RD.METHODSAmong 35 thick-walled CP cases (histologically pericardial thickening ≥2 mm), eight cases were aetiology identified. Using the diagnostic criteria for IgG4-RD, 11 cases were classified as IgG4-CP, whereas the remainder were considered true idiopathic CP (16 cases) and the clinical pathological features were evaluated.RESULTSCompared with the other groups, the IgG4-CP group was more common in men and associated with low-grade fever and massive pericardial effusion with frequent recurrence. Deaths resulting from heart failure occurred in a few cases of the IgG4-CP group, but not in other groups. An increase in C-reactive protein and a high positivity rate of anti-nuclear antibodies frequently occurred in the IgG4-CP group. Histologically, the IgG4-CP group included lymphoid follicle, eosinophil infiltration and few calcifications.CONCLUSIONSPericardial IgG4-RD occurs not only as nodular lesions, but also as thick-walled CP, and accounts for approximately 40% of thick-walled CP cases of unknown cause. The predominant clinical characteristic was refractory and recurrent pericardial effusion. Recognising IgG4-RD as a cause of CP is important to initiate appropriate therapy.

100 项与 Kanazawa University Hospital 相关的药物交易

登录后查看更多信息

100 项与 Kanazawa University Hospital 相关的转化医学

登录后查看更多信息